Phillips Courtney Sells 2,012 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Phillips Courtney sold 2,012 shares of the business’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total transaction of $52,332.12. Following the transaction, the insider owned 7,007 shares of the company’s stock, valued at $182,252.07. This trade represents a 22.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Phillips Courtney also recently made the following trade(s):

• On Wednesday, September 2nd, Phillips Courtney sold 1,981 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.47, for a total value of $52,437.07.

Maze Therapeutics Price Performance

NASDAQ:MAZE opened at $26.21 on Friday. Maze Therapeutics, Inc. has a 52-week low of $14.27 and a 52-week high of $53.65. The stock has a fifty day moving average of $28.69 and a 200 day moving average of $31.17. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of -10.40 and a beta of 2.17.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.76). On average, research analysts expect that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on MAZE. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Wall Street Zen cut shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, BTIG Research reissued a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a report on Wednesday, August 12th. Three analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $66.00.

Hedge Funds Weigh In On Maze Therapeutics

Several institutional investors have recently modified their holdings of MAZE. TRV GP IV LLC purchased a new position in shares of Maze Therapeutics during the 2nd quarter valued at about $133,502,907. ARCH Venture Management LLC bought a new stake in Maze Therapeutics in the 2nd quarter worth approximately $122,983,582. BlackRock Inc. purchased a new stake in Maze Therapeutics in the second quarter worth approximately $104,525,000. Jupiter Topco LLC purchased a new stake in Maze Therapeutics in the second quarter worth approximately $101,764,000. Finally, Janus Henderson Group PLC grew its position in Maze Therapeutics by 318.0% during the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock valued at $130,197,000 after acquiring an additional 2,390,713 shares during the last quarter.

Trending Headlines about Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.